ENDOBIOGENIC MEDICINE SOCIETY CIC

Company limited by guarantee

Company Registration Number:
10742696 (England and Wales)

Unaudited statutory accounts for the year ended 30 April 2024

Period of accounts

Start date: 1 May 2023

End date: 30 April 2024

ENDOBIOGENIC MEDICINE SOCIETY CIC

Contents of the Financial Statements

for the Period Ended 30 April 2024

Profit and loss
Balance sheet
Additional notes
Balance sheet notes
Community Interest Report

ENDOBIOGENIC MEDICINE SOCIETY CIC

Profit And Loss Account

for the Period Ended 30 April 2024

2024 2023


£

£
Turnover: 900 3,350
Cost of sales: ( 1,000 ) ( 427 )
Gross profit(or loss): (100) 2,923
Administrative expenses: ( 1,199 ) ( 396 )
Operating profit(or loss): (1,299) 2,527
Profit(or loss) before tax: (1,299) 2,527
Tax: ( 66 )
Profit(or loss) for the financial year: (1,299) 2,461

ENDOBIOGENIC MEDICINE SOCIETY CIC

Balance sheet

As at 30 April 2024

Notes 2024 2023


£

£
Current assets
Cash at bank and in hand: 401 1,015
Total current assets: 401 1,015
Creditors: amounts falling due within one year: 3 ( 751 ) ( 66 )
Net current assets (liabilities): (350) 949
Total assets less current liabilities: (350) 949
Total net assets (liabilities): (350) 949
Members' funds
Profit and loss account: (350) 949
Total members' funds: ( 350) 949

The notes form part of these financial statements

ENDOBIOGENIC MEDICINE SOCIETY CIC

Balance sheet statements

For the year ending 30 April 2024 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 30 January 2025
and signed on behalf of the board by:

Name: ANNA BETZ
Status: Director

The notes form part of these financial statements

ENDOBIOGENIC MEDICINE SOCIETY CIC

Notes to the Financial Statements

for the Period Ended 30 April 2024

  • 1. Accounting policies

    Basis of measurement and preparation

    These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

ENDOBIOGENIC MEDICINE SOCIETY CIC

Notes to the Financial Statements

for the Period Ended 30 April 2024

  • 2. Employees

    2024 2023
    Average number of employees during the period 0 0

ENDOBIOGENIC MEDICINE SOCIETY CIC

Notes to the Financial Statements

for the Period Ended 30 April 2024

3. Creditors: amounts falling due within one year note

2024 2023
£ £
Taxation and social security 66
Other creditors 751
Total 751 66

COMMUNITY INTEREST ANNUAL REPORT

ENDOBIOGENIC MEDICINE SOCIETY CIC

Company Number: 10742696 (England and Wales)

Year Ending: 30 April 2024

Company activities and impact

The company has offered information for members of the public and introductory training to herbalists interested in Endobiogenic Medicine. EMS offered training courses to suitably qualified therapists and medical professionals via a student organisation at Middlesex university. The company is a small community interest company and thus does not require a social audit report. For the year ending 30/04/2024, the company was entitled to exemptions from audit under section 477 of the companies Act, 2006.

Consultation with stakeholders

No consultation with stakeholders

Directors' remuneration

No remuneration was received

Transfer of assets

No transfer of assets other than for full consideration

This report was approved by the board of directors on
30 January 2025

And signed on behalf of the board by:
Name: ANNA BETZ
Status: Director